Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients von PEOPLES, George E, GURNEY, Jennifer M, HUEMAN, Matthew T, WOLL, Mike M, RYAN, Gayle B, STORRER, Catherine E, FISHER, Christine, SHRIVER, Craig D, IOANNIDES, Constantin G, PONNIAH, Sathibalan

Volltext

Comparison of Benefits on Myocardial Performance of Cellular Cardiomyoplasty with Skeletal Myoblasts and Fibroblasts von Hutcheson, Kelley A., Atkins, B. Zane, Hueman, Matthew T., Hopkins, M. Benjamin, Glower, Donald D., Taylor, Doris A.

Volltext

Phase I Clinical Trial of a HER-2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients von HUEMAN, Matthew T, DEHQANZADA, Zia A, PONNIAH, Sathibalan, PEOPLES, George E, NOVAK, Thomas E, GURNEY, Jennifer M, WOLL, Michael M, RYAN, Gayle B, STORRER, Catherine E, FISHER, Christine, MCLEOD, David G, IOANNIDES, Constantine G

Volltext

Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients von DEHQANZADA, Zia A, STORRER, Catherine E, HUEMAN, Matthew T, FOLEY, Rebecca J, HARRIS, Katie A, JAMA, Yusuf H, KAO, Tzu-Cheg, SHRIVER, Craig D, PONNIAH, Sathibalan, PEOPLES, George E

Volltext

Abstract P4-06-09: HER2+ and HER2- luminal B subtypes have similar overall survival and histologic grade distributions von Chen, Y, Kovatich, AJ, Fantacone-Campbell, JL, Hooke, JA, Kvecher, L, Kovatich, AW, Gallagher, CM, Hueman, MT, Hyslop, T, Mural, RJ, Shriver, CD, Rui, H, Hu, H

Volltext

Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium von Atkins, B.Zane, Hueman, Matthew T, Meuchel, Jennifer M, Cottman, Maisha J, Hutcheson, Kelley A, Taylor, Doris A

Volltext

Cellular Cardiomyoplasty Improves Diastolic Properties of Injured Heart von Atkins, B.Zane, Hueman, Matthew T., Meuchel, Jennifer, Hutcheson, Kelley A., Glower, Donald D., Taylor, Doris A.

Volltext

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/ neu peptide (AE37) von Gates, JD, Benavides, LC, Carmichael, MG, Hueman, MT, Holmes, JP, Khoo, S, Stojadinovic, A, von Hofe, E, Ponniah, S, Peoples, GE

Volltext